Dec202021

How patients can be involved in paediatric clinical trials at regulatory level? (Interview with EURORDIS-Rare Diseases Europe)

Maria Cavaller (Patient Engagement Manager) and Gulcin Gumus (Research and Policy Project Manager) are from patient organisation EURORDIS-Rare Diseases Europe, which is a c4c project partner. We talked to them about how patient organizations can take part in the c4c project, the importance of engaging young patients in research and having patients as equal partners…

Details

Christmas message from the c4c Project Leadership Team

c4c is a success. During 2021 c4c actions have influenced other organizations and shown why c4c is important. Despite many difficulties, c4c is very effective because of the dedication by everyone who works on c4c. The hard work and dedication are paying off as we follow the c4c vision and mission. The impacts made by…

Details
Dec202021

c4c Multi-Stakeholder Meeting on Paediatric Atopic Dermatitis (AD)

1 – 2 March 2022 – 4:00PM – 7:30PM CET (both days) – Virtual event Call for Expression of Interest (deadline: 14 January 2022) conect4children is pleased to announce that the second c4c International Multi-Stakeholder Meeting (MSM) will address paediatric Atopic Dermatitis (AD) and will take place VIRTUALLY on 1-2 MARCH 2022. The meeting is…

Details

c4c team presentation post: Rebecca Leary

Meet the team behind c4c! We’re a diverse group of people from many different backgrounds, but all of us are working towards a common goal: better medicines for children through European clinical trials. Today’s spotlight is on Rebecca ‘Becca’ Leary, one of our project managers. “I work at the John Walton Muscular Dystrophy Research Centre…

Details
Oct212021
Sep272021

Ready to be involved in conect4children?

Traditionally children and young people have been excluded from participating in clinical trials or have not had the opportunity to be involved in the design of clinical studies. However, this  doesn’t mean that involving paediatric patients is not feasible and involving patients does have important benefits. It’s time to shift from a drug-centric approach towards…

Details